Skip to Main content Skip to Navigation
Journal articles

Use of β-Blockers in Pulmonary Hypertension

Abstract : Contrasting with the major attention that left heart failure has received, right heart failure remains understudied both at the preclinical and clinical levels. However, right ventricle failure is a major predictor of outcomes in patients with precapillary pulmonary hypertension because of pulmonary arterial hypertension, and in patients with postcapillary pulmonary hypertension because of left heart disease. In pulmonary hypertension, the status of the right ventricle is one of the most important predictors of both morbidity and mortality. Paradoxically, there are currently no approved therapies targeting the right ventricle in pulmonary hypertension. By analogy with the key role of β-blockers in the management of left heart failure, some authors have proposed to use these agents to support the right ventricle function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of β-blockers in pulmonary hypertension.
Complete list of metadatas

Cited literature [60 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01502296
Contributor : Frédéric Perros <>
Submitted on : Wednesday, April 5, 2017 - 12:08:45 PM
Last modification on : Wednesday, September 16, 2020 - 5:50:30 PM
Long-term archiving on: : Thursday, July 6, 2017 - 1:13:44 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Frédéric Perros, Frances de Man, Harm Bogaard, Fabrice Antigny, Gérald Simonneau, et al.. Use of β-Blockers in Pulmonary Hypertension. Circulation. Heart failure, Lippincott Williams & Wilkins, 2017, 10 (4), pii: e00370. ⟨10.1161/CIRCHEARTFAILURE.116.003703⟩. ⟨inserm-01502296⟩

Share

Metrics

Record views

219